Product Description
Carbamazepine is used to treat certain types of seizures (epilepsy). It is also used to relieve pain due to trigeminal neuralgia (tic douloureux) and in the treatment of bipolar disorder (manic-depressive illness). Carbamazepine works in the brain and nervous system to control seizures, pain, and bipolar disorder. (Sourced from: https://www.mayoclinic.org/drugs-supplements/carbamazepine-oral-route/side-effects/drg-20062739?p=1)
Mechanisms of Action: CYP3A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Seizures | Seizures | Bipolar Disorder | Acute Pain | Neuralgia | Pain Unspecified | Trigeminal Neuralgia
Known Adverse Events: Diplopia | Dizziness | Headache | Pain Unspecified | Anemia | Ataxia | Pruritus | Asthenia | Constipation
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, Germany, United Kingdom, United States
Active Clinical Trial Count: 21
Highest Development Phases
Phase 1: COVID-19|Healthy Volunteers|Idiopathic Pulmonary Fibrosis|Male Breast Cancer|Non-Small-Cell Lung Cancer|Parkinson's Disease|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| D8532C00006 | P1 |
Recruiting |
Male Breast Cancer |
2025-02-23 |
|
| MK-5684-012 | P1 |
Recruiting |
Prostate Cancer |
2025-02-04 |
|
| C5091009 | P1 |
Recruiting |
Healthy Volunteers |
2025-01-17 |
|
| J2A-MC-GZPJ | P1 |
Completed |
Healthy Volunteers |
2024-07-23 |